Hematopoiesis

Preemptive lamivudine inhibits hepatitis B effects after transplantation

Published in Hepatitis Weekly, September 16th, 2002

by Sonia Nichols, senior medical writer - Lamivudine can be used to curb hepatitis B virus (HBV) exacerbation in people who receive hematopoietic cell transplantations, scientists report.

The lamivudine therapy should be started at least a week before transplantation, according to medical investigators at the University of Hong Kong in China.

"We studied 20 consecutive hepatitis B surface antigen (HBsAg)-positive recipients of allogeneic hematopoietic cell transplantation who received lamivudine 100 mg daily starting a week before transplantation until week 52 after transplantation," said George K.K. Lau, the report's lead investigator.

...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Hepatitis Weekly

Source: Hepatitis Weekly (2002-09-16)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry